Technical Specialist
Erick Salvador Rocha, Ph.D., leverages his background in immunology and molecular biology to assist clients with patent prosecution matters related to biologics, gene therapies, and pharmaceuticals.
Before joining Finnegan, Erick conducted doctoral research at Yale University, where he studied inflammatory processes and macrophage signaling and contributed to peer reviewed publications. His technical expertise in microbiology, immunology, and cell biology allows him to translate complex experimental data into clear, prosecution-ready narratives. Erick’s legal experience includes developing and implementing global prosecution strategies in fields related to gene-editing (e.g., CRISPR) and gene therapies.
Erick is passionate about teaching and mentoring. During his doctoral studies, he served as a teaching fellow, trained five high-school and undergraduate students, and mentored over fifteen first-year graduate students.
Coauthor. “Single Cell Analysis Reveals a Subset of High IL12p40–Secreting Dendritic Cells within Mouse Bone Marrow–Derived Macrophages Differentiated with M CSF,” Journal of Immunology, 2024.
Coauthor. “Genomics of Clostridium taeniosporum, an organism which forms endospores with ribbon like appendages,” PLOS ONE, 2018.
Global prosecution and portfolio management for major pharmaceutical company
Finnegan is lead and preferred IP strategy counsel for one of the largest pharmaceutical companies in the world, handling all aspects of prosecution and portfolio management for multiple top-tier products for the client. The work spans the gamut from drafting and prosecution through larger strategic planning, patent term extension, and pre-litigation preparation on blockbuster small molecule and biologic products in the oncology, rheumatology, immunology, neuromuscular, and cell and gene therapy spaces.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.